{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:28:44Z","timestamp":1789972124453,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T00:00:00Z","timestamp":1389139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-230x-14-6","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T13:22:31Z","timestamp":1389187351000},"source":"Crossref","is-referenced-by-count":34,"title":["Osteonecrosis of the jaw in a Crohn\u2019s disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report"],"prefix":"10.1186","volume":"14","author":[{"given":"Raimund HM","family":"Preidl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ebker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Raithel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Wehrhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich W","family":"Neukam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Stockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,8]]},"reference":[{"key":"1038_CR1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jamda.2007.06.005","volume":"8","author":"HK Kamel","year":"2007","unstructured":"Kamel HK: Update on osteoporosis management in long-term care: focus on bisphosphonates. J Am Med Dir Assoc. 2007, 8: 434-440. 10.1016\/j.jamda.2007.06.005.","journal-title":"J Am Med Dir Assoc"},{"key":"1038_CR2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","volume":"98","author":"RE Coleman","year":"2008","unstructured":"Coleman RE: Risks and benefits of bisphosphonates. Br J Cancer. 2008, 98: 1736-1740. 10.1038\/sj.bjc.6604382.","journal-title":"Br J Cancer"},{"key":"1038_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0278-2391(09)01877-1","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20132009 update. J Oral Maxillofac Surg. 2009, 67: 2-12.","journal-title":"J Oral Maxillofac Surg"},{"key":"1038_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003, 61: 1115-1117. 10.1016\/S0278-2391(03)00720-1.","journal-title":"J Oral Maxillofac Surg"},{"key":"1038_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.joms.2012.07.049","volume":"71","author":"KE Fleisher","year":"2013","unstructured":"Fleisher KE, Jolly A, Venkata UD, Norman RG, Saxena D, Glickman RS: Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. J Oral Maxillofac Surg. 2013, 71: 513-519. 10.1016\/j.joms.2012.07.049.","journal-title":"J Oral Maxillofac Surg"},{"key":"1038_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","volume":"35","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J. 2009, 35: 119-130. 10.1111\/j.1747-4477.2009.00213.x.","journal-title":"Aust Endod J"},{"key":"1038_CR7","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","volume":"65","author":"RE Marx","year":"2007","unstructured":"Marx RE, Cillo JE, Ulloa JJ: Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007, 65: 2397-2410. 10.1016\/j.joms.2007.08.003.","journal-title":"J Oral Maxillofac Surg"},{"key":"1038_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcms.2012.10.018","volume":"41","author":"P Stockmann","year":"2013","unstructured":"Stockmann P, Nkenke E, Englbrecht M, Schlittenbauer T, Wehrhan F, Rauh C, Beckmann MW, Fasching PA, Kreusch T, Mackensen A, et al: Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. J Craniomaxillofac Surg. 2013, 41: 71-75. 10.1016\/j.jcms.2012.10.018.","journal-title":"J Craniomaxillofac Surg"},{"key":"1038_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(06)70726-4","volume":"7","author":"CA Migliorati","year":"2006","unstructured":"Migliorati CA, Siegel MA, Elting LS: Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006, 7: 508-514. 10.1016\/S1470-2045(06)70726-4.","journal-title":"Lancet Oncol"},{"key":"1038_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1479-5876-9-135","volume":"9","author":"P Stockmann","year":"2011","unstructured":"Stockmann P, Wehrhan F, Schwarz-Furlan S, Stelzle F, Trabert S, Neukam FW, Nkenke E: Increased human defensine levels hint at an inflammatory etiology of bisphosphonate-associated osteonecrosis of the jaw: an immunohistological study. J Transl Med. 2011, 9: 135-10.1186\/1479-5876-9-135.","journal-title":"J Transl Med"},{"key":"1038_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000151371","volume":"189","author":"MR Allen","year":"2009","unstructured":"Allen MR: Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs. 2009, 189: 289-294. 10.1159\/000151371.","journal-title":"Cells Tissues Organs"},{"key":"1038_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00198-010-1177-6","volume":"22","author":"A Kyrgidis","year":"2011","unstructured":"Kyrgidis A, Toulis KA: Denosumab-related osteonecrosis of the jaws. Osteoporos Int. 2011, 22: 369-370. 10.1007\/s00198-010-1177-6.","journal-title":"Osteoporos Int"},{"key":"1038_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/rheumatology\/kes351","volume":"52","author":"T Ebker","year":"2013","unstructured":"Ebker T, Rech J, von Wilmowsky C, Neukam FW, Stockmann P: Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy. Rheumatology (Oxford). 2013, 52: 218-220. 10.1093\/rheumatology\/kes351.","journal-title":"Rheumatology (Oxford)"},{"key":"1038_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00520-009-0688-1","volume":"18","author":"P Stockmann","year":"2010","unstructured":"Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, Neukam FW, Nkenke E: Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer. 2010, 18: 449-460. 10.1007\/s00520-009-0688-1.","journal-title":"Support Care Cancer"},{"key":"1038_CR15","doi-asserted-by":"publisher","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","volume":"12","author":"AJ Roelofs","year":"2006","unstructured":"Roelofs AJ, Thompson K, Gordon S, Rogers MJ: Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006, 12: 6222s-6230s. 10.1158\/1078-0432.CCR-06-0843.","journal-title":"Clin Cancer Res"},{"key":"1038_CR16","first-page":"196","volume":"51","author":"Y Nagano","year":"2012","unstructured":"Nagano Y, Matsui H, Shimokawa O, Hirayama A, Nakamura Y, Tamura M, Rai K, Kaneko T, Hyodo I: Bisphosphonate-induced gastrointestinal mucosal injury is mediated by mitochondrial superoxide production and lipid peroxidation. J Clin Biochem Nutr. 2012, 51: 196-203.","journal-title":"J Clin Biochem Nutr"},{"key":"1038_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1517\/14712590903048909","volume":"9","author":"GW Dryden Jr","year":"2009","unstructured":"Dryden GW: Overview of biologic therapy for Crohn's disease. Expert Opin Biol Ther. 2009, 9: 967-974. 10.1517\/14712590903048909.","journal-title":"Expert Opin Biol Ther"},{"key":"1038_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10067-012-2113-2","volume":"32","author":"T Matsumoto","year":"2013","unstructured":"Matsumoto T, Nakamura I, Miura A, Momoyama G, Ito K: New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. Clin Rheumatol. 2013, 32: 271-275. 10.1007\/s10067-012-2113-2.","journal-title":"Clin Rheumatol"},{"key":"1038_CR19","first-page":"700","volume":"30","author":"C Joyau","year":"2012","unstructured":"Joyau C, Veyrac G, Dixneuf V, Jolliet P: Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?. Clin Exp Rheumatol. 2012, 30: 700-706.","journal-title":"Clin Exp Rheumatol"},{"key":"1038_CR20","first-page":"327","volume":"72","author":"JP Hauzeur","year":"2009","unstructured":"Hauzeur JP, Malaise M, Gangji V: Osteonecrosis in inflammatory bowel diseases: a review of the literature. Acta Gastroenterol Belg. 2009, 72: 327-334.","journal-title":"Acta Gastroenterol Belg"},{"key":"1038_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1155\/1997\/953252","volume":"11","author":"HJ Freeman","year":"1997","unstructured":"Freeman HJ: Osteomyelitis and osteonecrosis in inflammatory bowel disease. Can J Gastroenterol. 1997, 11: 601-606.","journal-title":"Can J Gastroenterol"},{"key":"1038_CR22","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1055\/s-2005-872607","volume":"130","author":"B Lanyi","year":"2005","unstructured":"Lanyi B, Dienes HP, Kruis W: Recurrent aseptic osteonecrosis in Crohn's disease - extraintestinal manifestation or steroid related complication?. Dtsch Med Wochenschr. 2005, 130: 1944-1947. 10.1055\/s-2005-872607.","journal-title":"Dtsch Med Wochenschr"},{"key":"1038_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2036.2005.02231.x","volume":"21","author":"G Klingenstein","year":"2005","unstructured":"Klingenstein G, Levy RN, Kornbluth A, Shah AK, Present DH: Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Aliment Pharmacol Ther. 2005, 21: 243-249. 10.1111\/j.1365-2036.2005.02231.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"1038_CR24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","volume":"142","author":"P Rutgeerts","year":"2012","unstructured":"Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, Kumar A, Lazar A, Camez A, et al: Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012, 142: 1102-1111. 10.1053\/j.gastro.2012.01.035. e1102","journal-title":"Gastroenterology"},{"key":"1038_CR25","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1002\/art.10388","volume":"46","author":"M Ziolkowska","year":"2002","unstructured":"Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, et al: High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum. 2002, 46: 1744-1753. 10.1002\/art.10388.","journal-title":"Arthritis Rheum"},{"key":"1038_CR26","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1136\/ard.2007.071910","volume":"66","author":"I Gonzalez-Alvaro","year":"2007","unstructured":"Gonzalez-Alvaro I, Ortiz AM, Tomero EG, Balsa A, Orte J, Laffon A, Garcia-Vicuna R: Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis. 2007, 66: 1675-1678. 10.1136\/ard.2007.071910.","journal-title":"Ann Rheum Dis"},{"key":"1038_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4103\/0973-1482.92020","volume":"7","author":"NH Akhtar","year":"2011","unstructured":"Akhtar NH, Afzal MZ, Ahmed AA: Osteonecrosis of jaw with the use of denosumab. J Cancer Res Ther. 2011, 7: 499-500. 10.4103\/0973-1482.92020.","journal-title":"J Cancer Res Ther"},{"key":"1038_CR28","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-2036.2005.02309.x","volume":"21","author":"C Shen","year":"2005","unstructured":"Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005, 21: 251-258. 10.1111\/j.1365-2036.2005.02309.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"1038_CR29","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1111\/j.1440-1746.2010.06407.x","volume":"25","author":"IC Lawrance","year":"2010","unstructured":"Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, Gearry RB, Florin TH: Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol. 2010, 25: 1732-1738. 10.1111\/j.1440-1746.2010.06407.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"1038_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-2796.2012.02515.x","volume":"271","author":"M Gersemann","year":"2012","unstructured":"Gersemann M, Wehkamp J, Stange EF: Innate immune dysfunction in inflammatory bowel disease. J Intern Med. 2012, 271: 421-428. 10.1111\/j.1365-2796.2012.02515.x.","journal-title":"J Intern Med"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-230X-14-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-14-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-14-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-14-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T03:50:21Z","timestamp":1548129021000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/1471-230X-14-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1186\/1471-230x-14-6","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,8]]},"article-number":"6"}}